Exempts drug manufacturers and distributors from pharmacist licensing for dialysis-related drugs and devices.
New Jersey S2875 exempts drug manufacturers and wholesale drug distributors from pharmacist licensing requirements when distributing dialysate drugs or devices for home dialysis to patients with end-stage renal disease. This exemption applies if the drugs and devices are FDA-approved, held by a properly registered entity, delivered in original packaging, and sent directly to patients or healthcare providers upon a physician's order. The bill also mandates periodic oversight by a licensed pharmacist.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
Analyze for Free
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.